Stephen Basil Thomas
CIK: 0002027962
Associated companies
Transaction History
| CLYM | ▼ Sell | Open Market | 100,000 | $1.4M | 9/15/2026 | View on chart |
| CLYM | ▼ Sell | Open Market | 16,313 | $114K | 2/26/2026 | View on chart |
| CLYM | ▼ Sell | Open Market | 33,687 | $236K | 2/25/2026 | View on chart |
| CLYM | ▼ Sell | Open Market | 10,000 | $58K | 2/13/2026 | View on chart |
| CLYM | ▼ Sell | Open Market | 90,000 | $471K | 2/12/2026 | View on chart |
| CLYM | ▲ Buy | Grant | 100,375 | $0 | 8/7/2025 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 25,094 | — | 6/27/2025 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 25,093 | — | 3/27/2025 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 50,188 | — | 1/1/2025 | View on chart |
| CLYM | ▲ Buy | Grant | 103,907 | — | 6/27/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets
Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets. Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.